论文部分内容阅读
背景与目的:研究证实,食管癌患者存在明显的细胞免疫功能抑制,手术创伤可引起食管癌的暂时性细胞免疫抑制。本研究旨在观察细胞免疫支持治疗对食管癌患者围术期细胞免疫机能的影响。方法:采用前瞻性的临床随机对照研究,60例施行二野清扫术的胸段食管癌患者随机分成对照组与试验组,试验组术后应用参芪注射液,对照组术后不应用任何免疫制剂。抽取两组患者术前、术后3天、术后9天的外周血,分别利用KL型肿瘤免疫图像分析系统检测T淋巴细胞AgNOR活性表达,流式细胞术分析T淋巴细胞亚群。结果:术后第3天,试验组患者外周血中CD3+CD4+、CD4+/CD8+水平明显优于对照组(P<0.05);术后第9天,试验组患者外周血中AgNOR、CD3+、CD3+CD4+、CD4+/CD8+、CD4+CD25+水平明显优于对照组(P<0.05)。两组患者1年生存率没有显著性差异(P>0.05)。结论:应用参芪注射液能明显改善二野清扫术胸段食管癌患者因肿瘤及手术引起的免疫细胞抑制作用。
BACKGROUND & AIM: Studies have shown that there is significant inhibition of cellular immune function in patients with esophageal cancer, and surgical trauma can cause transient cellular immunosuppression in esophageal cancer. The purpose of this study was to investigate the effect of cellular immune support on the cellular immunity during perioperative period in patients with esophageal cancer. Methods: A prospective clinical randomized controlled trial of 60 patients with esophageal cancer of the thoracic esophagus who underwent mammography was randomly divided into control group and experimental group. The patients in the experimental group were treated with Shenqi injection after operation and the control group was not given any postoperative immunization preparation. Peripheral blood samples of three groups were collected before operation, 3 days after operation and 9 days after operation. The expression of AgNOR in T lymphocytes was detected by KL immunohistochemical analysis system. The T lymphocyte subsets were analyzed by flow cytometry. Results: The levels of CD3 + CD4 + and CD4 + / CD8 + in the peripheral blood of patients in the experimental group were significantly better than those in the control group on the third day after operation (P <0.05). On the 9th day after operation, the levels of AgNOR, CD3 +, CD3 + CD4 +, CD4 + / CD8 + and CD4 + CD25 + were significantly higher than those of the control group (P <0.05). There was no significant difference in one-year survival rate between the two groups (P> 0.05). Conclusion: The application of Shenqi Injection can significantly improve the tumor suppression in patients with thoracic esophageal cancer during the Second Stage Radiofrequency ablation.